학술논문

Clinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study
Document Type
article
Author
Bernhard MlecnikToshihiko TorigoeGabriela BindeaBoryana PopivanovaMingli XuTomonobu FujitaShoichi HazamaNobuaki SuzukiHiroaki NaganoKiyotaka OkunoYoshihiko HirohashiTomohisa FuruhataIchiro TakemasaPrabhudas PatelHemangini VoraBirva ShahJayendrakumar B. PatelKruti N. RajvikShashank J. PandyaShilin N. ShuklaYili WangGuanjun ZhangTakayuki YoshinoHiroya TaniguchiCarlo BifulcoAlessandro LugliJiun-Kae Jack LeeInti ZlobecTilman T. RauMartin D. BergerIris D. NagtegaalElisa Vink-BörgerArndt HartmannCarol I. GeppertJulie KolwelterSusanne MerkelRobert GrützmannMarc Van den EyndeAnne Jouret-MourinAlex KartheuserDaniel LéonardChristophe RemueJulia WangPrashant BaviMichael H. A. RoehrlPamela S. OhashiLinh T. NguyenSeongJun HanHeather L. MacGregorSara Hafezi-BakhtiariBradly G. WoutersGiuseppe V. MasucciEmilia AnderssonEva ZavadovaMichal VockaJan SpacekLubos PetruzelkaBohuslav KonopasekPavel DundrHelena SkalovaKristyna NemejcovaGerardo BottiFabiana TatangeloPaolo DelrioGennaro CilibertoMichele MaioLuigi LaghiFabio GrizziFlorence MarliotTessa FredriksenBénédicte ButtardLucie LafontainePauline MabyAmine MajdiAssia HijaziCarine El SissyAmos KirilovskyAnne BergerChristine LagorceChristopher PaustianCarmen Ballesteros-MerinoJeroen DijkstraCarlijn Van de WaterShannon van Lent-van VlietNikki KnijnAna-Maria MușinăDragos-Viorel ScripcariuFrancesco M. MarincolaPaolo A. AsciertoBernard A. FoxFranck PagèsYutaka KawakamiJérôme Galon
Source
Cancers, Vol 14, Iss 18, p 4346 (2022)
Subject
Immunoscore
colon cancer
tumor microenvironment
immune response
classification
prognostic markers
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Language
English
ISSN
14184346
2072-6694
Abstract
BACKGROUND: In this study, we evaluated the prognostic value of Immunoscore in patients with stage I–III colon cancer (CC) in the Asian population. These patients were originally included in an international study led by the Society for Immunotherapy of Cancer (SITC) on 2681 patients with AJCC/UICC-TNM stages I–III CC. METHODS: CD3+ and cytotoxic CD8+ T-lymphocyte densities were quantified in the tumor and invasive margin by digital pathology. The association of Immunoscore with prognosis was evaluated for time to recurrence (TTR), disease-free survival (DFS), and overall survival (OS). RESULTS: Immunoscore stratified Asian patients (n = 423) into different risk categories and was not impacted by age. Recurrence-free rates at 3 years were 78.5%, 85.2%, and 98.3% for a Low, Intermediate, and High Immunoscore, respectively (HR[Low-vs-High] = 7.26 (95% CI 1.75−30.19); p = 0.0064). A High Immunoscore showed a significant association with prolonged TTR, OS, and DFS (p < 0.05). In Cox multivariable analysis stratified by center, Immunoscore association with TTR was independent (HR[Low-vs-Int+High] = 2.22 (95% CI 1.10–4.55) p = 0.0269) of the patient’s gender, T-stage, N-stage, sidedness, and MSI status. A significant association of a High Immunoscore with prolonged TTR was also found among MSS (HR[Low-vs-Int+High] = 4.58 (95% CI 2.27−9.23); p ≤ 0.0001), stage II (HR[Low-vs-Int+High] = 2.72 (95% CI 1.35−5.51); p = 0.0052), low-risk stage-II (HR[Low-vs-Int+High] = 2.62 (95% CI 1.21−5.68); p = 0.0146), and high-risk stage II patients (HR[Low-vs-Int+High] = 3.11 (95% CI 1.39−6.91); p = 0.0055). CONCLUSION: A High Immunoscore is significantly associated with the prolonged survival of CC patients within the Asian population.